Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
S2Medical AB is a medical technology company that specializes in providing advanced wound care solutions. The primary function of this company is to develop and supply innovative products aimed at enhancing wound healing and patient comfort. S2Medical AB's offerings include specialized dressings and devices designed to promote faster recovery rates and improve the overall treatment process for wounds. Notably, the company focuses on the integration of new technologies, such as bioactive and biocompatible materials, to facilitate better health outcomes. Operating internationally, S2Medical AB impacts several sectors including healthcare, biotechnology, and medical research. The company's emphasis on research and development ensures it stays at the forefront of medical innovation. In the financial market, S2Medical AB plays a crucial role in driving advancements in healthcare, attracting interest from hospitals, clinics, and medical professionals seeking effective wound care products. Through its commitment to innovation and quality, S2Medical AB contributes to enhancing patient care and elevating standards within the medical industry.
kr 0.00
+kr 0.00 (+0.00%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-18.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 2.2% YoY. Margins deteriorated 51.4pp alongside, both lines moving the wrong way.
Free cash flow declined 127% versus the prior year, cash generation momentum has weakened. ROIC dropped from 47.39% to -14.72%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 14M
▼ -2.2% YoY
Net Income (TTM)
-kr 10M
▼ -309.8% YoY
Op. Margin
-18.55%
▼ -51.4pp YoY
ROIC
-14.72%
▼ -62.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 1M
▼ -126.8% YoY
Op. Cash Flow (TTM)
-kr 759K
▼ -115.1% YoY
Net Debt
-kr 907K
Net Cash Position
Cash & Equiv.
kr 907K
3Y CAGR: +45.4%
Continue Research
S2Medical AB (S2M.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, S2Medical AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
S2Medical AB scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -18.5% operating margin and a -14.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh S2M.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.